$7.29
0.00%
Nasdaq, Thu, Oct 22 2026.
ISIN
US49372L1008
Symbol
KZR

Kezar Life Sciences Inc Stock price

$7.29
+0.00 0.00% 1M
-0.01 0.07% 6M
+1.00 15.90% YTD
+1.12 18.15% 1Y
-1.87 20.45% 3Y
-78.61 91.51% 5Y
-170.21 95.89% 10Y
-170.21 95.89% 20Y
Nasdaq, Closing price Thu, Oct 22 2026
+0.00 0.00%
ISIN
US49372L1008
Symbol
KZR
Industry

Is Kezar Life Sciences Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,102 stocks worldwide.

Key metrics

Basic
Market capitalization
-
Enterprise Value
-
Net debt
positive
Cash
$71.9m
Shares outstanding
7.3m
Valuation
P/E
negative
P/S | estimate
- | -
EV/Sales | estimate
- | -
EV/FCF | ex SBC
- | -
P/B
-
Financial Health
Equity Ratio
91.4%
Return on Equity
-80.0%
ROCE
-74.6%
ROIC
-
Debt/Equity
0.0
Share-Based Compensation & Dilution
SBC | % of Revenue
$9.0m | -
SBC as % of FCF
-
SBC Growth 1Y
-31.1%
Share Count Growth 1Y
0.4%
Shareholder Yield
-0.4%
Financials
Revenue | estimate
$0.0 | $0.0
EBITDA
$-51.4m
EBIT
$-52.3m
Net Income
$-56.0m
Free Cash Flow | ex SBC
$-51.8m | $-60.8m
Growth
Revenue | estimate
- | -
EBITDA
19.7%
EBIT
19.6%
Net Income
10.4%
Free Cash Flow
30.2%
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow | ex SBC
- | -
More
EPS
$-7.7
FCF per Share
$-7.1
Short interest
2.1%
Employees
9
Rev per Employee
$0.0

Kezar Life Sciences Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Kezar Life Sciences Inc forecast:

4x Buy
44%
5x Hold
56%

Analyst Opinions

9 Analysts have issued a Kezar Life Sciences Inc forecast:

Buy
44%
Hold
56%

Financial data from Kezar Life Sciences Inc

Dec '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 19 19
10% 10%
-
- Research and Development Expense 34 34
30% 30%
-
-51 -51
20% 20%
-
- Depreciation and Amortization 0.90 0.90
13% 13%
-
EBIT (Operating Income) EBIT -52 -52
20% 20%
-
Net Profit -56 -56
10% 10%
-

In millions USD.

Don't miss a Thing! We will send you all news about Kezar Life Sciences Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Kezar Life Sciences, Inc. is a clinical-stage biotechnology company, which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer in South San Francisco, California. Its product pipeline include KZR-616, KZR-261, and KZR-TBD. The company was founded by John Fowler, Christopher J. Kirk, and Jack Taunton on February 20, 2015 and is headquartered in South San Francisco, CA.

Head office United States
CEO Dr. Kirk
Employees 9
Founded 2015
Website kezarlifesciences.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today